Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.36 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.36 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orotic Acid SCHEMBL896843 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL366202 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL422601 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL161884 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL11903508 | 0.96 | ALDH1A1 (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL23859826 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL5148012 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL1854526 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL20518755 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL159382 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212191-B1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2022-10-05 | — | — | EP | claimed |
| US-11135181-B2 | Treatment for depression and depressive disorders | MEDLAB IP PTY LTD (AU) | 2021-10-05 | — | — | US | claimed |
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | CYPRUMED GMBH (AT) | 2021-02-02 | — | — | US | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | claimed |
| US-20170312232-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2017-11-02 | — | — | US | claimed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | claimed |
| EP-3212191-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | Medlab IP Pty Ltd. (AU) | 2017-09-06 | — | — | EP | claimed |
| WO-2016065419-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2016-05-06 | — | — | WO | claimed |
| US-20150335688-A1 | PROBIOTIC COMBINATIONS AND USES THEREOF | MEDLAB IP PTY LTD (AU) | 2015-11-26 | — | — | US | claimed |
| US-7939109-B1 | Method of treating neoplastic disease in a human or animal patient | CARTER JOHN | 2011-05-10 | — | — | US | claimed |
| US-20050123623-A1 | Pharmaceutical compositions and their use in the treatment of neoplastic disease | CARTER JOHN (GB) | 2005-06-09 | — | — | US | claimed |
| CN-1508131-A | Ferrous orotic acid, and preparing method and use thereof | 维奥（四川）生物技术有限公司 | 2004-06-30 | — | — | CN | claimed |
| CN-119569660-A | Orotic acid chelate salt and preparation method thereof | 南通励成生物工程有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-3212191-B1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2022-10-05 | — | — | EP | disclosed |
| US-11452761-B2 | Method for inhibiting renal hypofunction in non-human animal | KANEKA CORPORATION (JP) | 2022-09-27 | — | — | US | disclosed |
| EP-0870435-A1 | MINERAL COMPOSITION | TAIYO KAGAKU Co., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-4745099-A | ERYTHROPROTEIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1988-05-17 | — | — | US | disclosed |
| US-4732889-A | HUMAN ERYTHROPOIETIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1988-03-22 | — | — | US | disclosed |
| EP-0142790-A2 | An antianaemic composition and a process for producing the same | Tanaka, Kentaro (JP) | 1985-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | SLC30A5, SLC30A6, SON | LMNA 4870/4885ALDH1A1 3933/4885CYP1A2 3809/4885 |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | SLC30A5, SLC39A11, SLC30A6 | LMNA 4860/4885ALDH1A1 3473/4885CYP1A2 3593/4885 |
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | SLC30A5, SLC39A11, SLC30A6 | LMNA 4860/4885ALDH1A1 3473/4885CYP1A2 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.